Sepideh Gholami
University of California, Davis
76 Papers
234 Citations
Sepideh Gholami is an academic researcher from University of California, Davis. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 18, co-authored 51 publications. Previous affiliations of Sepideh Gholami include Stanford University & Memorial Sloan Kettering Cancer Center.
Chat about Author
Papers
Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma.
Emil Lou,Sho Fujisawa,Alexei Morozov,Afsar Barlas,Yevgeniy Romin,Yildirim Dogan,Sepideh Gholami,Andre L. Moreira,Katia Manova-Todorova,Malcolm A.S. Moore +9 more
TL;DR: The first evidence of tunneling nanotubes in human primary tumors and cancer cells is provided and it is proposed that these structures play an important role in cancer cell pathogenesis and invasion.
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Dan Morris,Erin D. Kennedy,Nancy N. Baxter,Al B. Benson,Andrea Cercek,May Cho,Kristen K. Ciombor,Chiara Cremolini,Anjee Davis,Dustin A. Deming,Marwan Fakih,Sepideh Gholami,Theodore S. Hong,Ishmael Jaiyesimi,Kelsey A. Klute,Christopher H. Lieu,Hanna K. Sanoff,John G. Strickler,Sarah White,Jason Willis,Cathy Eng +20 more
TL;DR: Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases andMultidisciplinary team management and shared decision making are recommended.
168
Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases.
Georgios A. Margonis,Kazunari Sasaki,Sepideh Gholami,Yuhree Kim,Nikolaos Andreatos,Neda Rezaee,Amar Deshwar,Stefan Buettner,Stefan Buettner,Peter J. Allen,T.P. Kingham,Timothy M. Pawlik,Jin He,John L. Cameron,William R. Jarnagin,Christopher L. Wolfgang,M.I. D'Angelica,Matthew J. Weiss +17 more
TL;DR: This study sought to develop a clinical risk score for resectable colorectal liver metastasis by combining clinicopathological and clinically available biological indicators, including KRAS, by combininginic and biological indicators.
145
Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
J. Gagnière,J. Gagnière,Aurélien Dupré,Sepideh Gholami,Denis Pezet,Thomas Boerner,Mithat Gonen,T.P. Kingham,Peter J. Allen,Vinod P. Balachandran,Ronald P. De Matteo,Jeffrey A. Drebin,Rona Yaeger,Nancy E. Kemeny,William R. Jarnagin,Michael I. D’Angelica +15 more
TL;DR: Patients with resectable BRAF-mut CRLM are rare among patients selected for surgery and more commonly present with multiple synchronous tumors, however, long-term survival is possible and associated with node-negative primary tumors, CEA ≤ 200 μg/L and CRS < 4.
101
Size and Location are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors.
Sepideh Gholami,Michael R. Cassidy,Amanda Kirane,Deborah Kuk,Bhumika Zanchelli,C. R. Antonescu,Samuel Singer,Murray F. Brennan +7 more
TL;DR: Recurrence is highly associated with DSD and events occur as late as 16 years after initial presentation, including in patients with initially considered benign tumors, and patients with large tumors in the chest or abdominal/retroperitoneal cavity are at greatest risk.
87